QC Testing & QP Release
Clinical products and IMPs are sampled and analysed according to prepared pre-approved specifications using methodology developed and validated in-house. Release of products by our in-house QP is performed before distribution to the clinical sites.
Implementation of an established approach, using technologies to fully characterise both molecular level properties and bulk properties, can be applied either predictively, for optimisation purposes or for inclusion in regulatory documentation. These technologies can be applied during clinical development or to materials already in the market place. With respect to drug substance, close collaboration between CMC and API teams will ensure determination of the most appropriate form for pharmaceutical application, offering a long term view to successful project progression. Similarly, characterisation of excipients, or drug – excipient interactions, either throughout the recommended manufacturing process or in the final product, can be employed to ensure robust performance
CPhI WorldwideCPhI Worldwide will be attended by Nathalie Huther, Business Development Manager Europe. Nathalie will be located at the DIT stand: 9J40
CPhI WorldwideDates: 9th - 11th SeptemberLocation: Madrid, Spain
Nordic Life Science DaysNordic Life Science Days annual conference will be attended by Nathalie Huther, Business Development Manager Europe.
Nordic Life Science DaysDates: 10th - 12th SeptemberLocation: Stockholm, Sweden
PHSS & UCL Q3P Annual ConferencePHSS & UCL Q3P Annual Conference will be attended by Angela Fuller, Microbology Team Leader.
PHSS & UCL Q3P Annual ConferenceDates: 11th SeptemberLocation: UCL, London